{"filing":{"accession_number":"0001213900-26-080474","cik":"0001704287","ticker":"BJDX","company_name":"Bluejay Diagnostics, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"ea0298955-8k_bluejay.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026080474/ea0298955-8k_bluejay.htm"},"events":[{"id":19691,"run_id":17717,"accession_number":"0001213900-26-080474","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Bluejay announced successful completion of enrollment in the SYMON-II pivotal clinical validation study for its Symphony™ IL-6 diagnostic platform, achieving 750 patients ahead of schedule. This represents a material operational and clinical milestone for the pre-commercial medical device company, marking progress toward regulatory submission and commercialization of its key product candidate.","company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18859,"accession_number":"0001213900-26-080474","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Bluejay announced successful completion of enrollment in the SYMON-II pivotal clinical validation study for its Symphony™ IL-6 diagnostic platform, achieving 750 patients ahead of schedule. This is a material operational and clinical milestone for a pre-commercial medical device company, as it represents progress toward regulatory submission and commercialization of a key product candidate. The event is operational in nature (a clinical development milestone) rather than fitting a specific financial, governance, or legal category, and would affect a reasonable investor's assessment of the company's development trajectory and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:26:40.018492+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18859,"accession_number":"0001213900-26-080474","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Bluejay announced successful completion of enrollment in the SYMON-II pivotal clinical validation study for its Symphony™ IL-6 diagnostic platform, achieving 750 patients ahead of schedule. This is a material operational and clinical milestone for a pre-commercial medical device company, as it represents progress toward regulatory submission and commercialization of a key product candidate. The event is operational in nature (a clinical development milestone) rather than fitting a specific financial, governance, or legal category, and would affect a reasonable investor's assessment of the company's development trajectory and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:26:40.018492+00:00","company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","filing_date":"2026-07-22"}]}